KRIBIOLISA™ Lebrikizumab ELISA
Enzyme Immunoassay for the quantitative determination of Lebrikizumab in serum, plasma and cell culture supernatant
Receive your quote directly from the manufacturer.
Introduction:
Lebrikizumab is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. Lebrikizumab blocks interleukin 13 (IL-13), a cytokine (cell-signalling protein) that is produced by a type of white blood cell called Th2 cells.
Intended Use:
The KRIBIOLISA™ Lebrikizumab ELISA is used as an analytical tool for quantitative determination of Lebrikizumab in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Lebrikizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Lebrikizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Lebrikizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Lebrikizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
